Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 4Neuroblastoma 3Medulloblastoma 2Carcinoid Tumor 2von Hippel-Lindau Disease 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Prostatic Neoplasms 1Parathyroid Neoplasms 1Paraganglioma 1Multiple Endocrine Neoplasia 1Hypoglycemia 1Hyperparathyroidism 1Hypercalcemia 1Cancer Diagnosis 1

Interventions

Temozolomide 4Capecitabine 4Bevacizumab 3Leucovorin 2Fluorouracil 2Everolimus 2temsirolimus 1sapanisertib 1regorafenib 1pentetreotide 1pazopanib 1motesanib diphosphate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1batifiban 1aflibercept 1Sunitinib 1Sorafenib 1Sirolimus 1Panobinostat 1Oxaliplatin 1Octreotide 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Fentanyl 1Etoposide 1Doxorubicin 1Disulfides 1Cytidine Triphosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Somatostatinoma × gallium Ga 68 dotatate × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡